CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–#beigene–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET.
A live webcast can be accessed from the investors section of BeiGene�s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com.
Contacts
Investor
Kevin Mannix
+1 857-302-5189
ir@beigene.com
Media
Liza Heapes
+1 857-302-5663
media@beigene.com
Proposed final dividend of HK$0.76 cents per share HONG KONG SAR - Media OutReach Newswire…
HANOI, Vietnam--(BUSINESS WIRE)--Global IT services provider FPT Software recently entered a partnership with US-based no-code…
SINGAPORE--(BUSINESS WIRE)--CommunicAsia – Quectel Wireless Solutions, a global IoT solutions provider, is showcasing its latest…
SINGAPORE - Media OutReach Newswire - 28 May 2024 – AXS, a leading provider of…
A Delightful Fusion of Tradition and Versatility KUALA LUMPUR, MALAYSIA - Media OutReach Newswire -…
UBS accounting, billing, and inventory users to participate in eInvoicing beta testing in June, before…